Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Emerald Health and Lonza Enter Large-Scale Manufacturing Pact

    Emerald Health and Lonza Enter Large-Scale Manufacturing Pact

    Shimmer Launches Verisense Wearable Sensor Platform for Clinical Trials

    Shimmer Launches Verisense Wearable Sensor Platform for Clinical Trials

    Knight Therapeutics invests up to $125m in Latin America-focused Moksha8

    Knight Therapeutics invests up to $125m in Latin America-focused Moksha8

    Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

    Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

    AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

    AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EC Approves ADCETRIS with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

    EC Approves ADCETRIS with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

    EC Approves Bristol-Myers Squibb’s Sprycel in Combination with Chemotherapy for Treatment of Pediatric Patients

    EC Approves Bristol-Myers Squibb’s Sprycel in Combination with Chemotherapy for Treatment of Pediatric Patients

    Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China

    Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Emerald Health and Lonza Enter Large-Scale Manufacturing Pact

    Emerald Health and Lonza Enter Large-Scale Manufacturing Pact

    Shimmer Launches Verisense Wearable Sensor Platform for Clinical Trials

    Shimmer Launches Verisense Wearable Sensor Platform for Clinical Trials

    Knight Therapeutics invests up to $125m in Latin America-focused Moksha8

    Knight Therapeutics invests up to $125m in Latin America-focused Moksha8

    Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

    Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

    AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

    AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EC Approves ADCETRIS with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

    EC Approves ADCETRIS with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

    EC Approves Bristol-Myers Squibb’s Sprycel in Combination with Chemotherapy for Treatment of Pediatric Patients

    EC Approves Bristol-Myers Squibb’s Sprycel in Combination with Chemotherapy for Treatment of Pediatric Patients

    Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China

    Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

T3 Pharmaceuticals Wins Prestigious Falling Walls Venture Award for Its Bacterial Cancer Therapy

Content Team by Content Team
13th November 2018
in Americas, Drug Development, News

T3 Pharmaceuticals , a biotech company with a focus on immuno-oncology, announced it has been named “2018 Science Start-Up of the Year” by Falling Walls Venture. The award honors emerging scientist-entrepreneurs for their breakthrough business models.

The Falling Walls Conference in Berlin, Germany, annually invites the world’s leading scientists to identify trends, opportunities and solutions for global challenges and discover international breakthrough research. Falling Walls Venture showcases the most promising research based start-ups from all over the globe that tear down walls and overcome boundaries in their respective fields.

“We are honored to receive this prestigious award. We thank the jury for recognizing the medical potential of our immuno-oncology approach. Our sincerest thanks go to all our friends, partners and supporters and, particularly, to the University of Basel, who nominated us for this award”, commented Dr. Simon Ittig, CEO of T3 Pharma. “The Falling Walls Venture Award confirms our aspirations to advance our therapy into clinical use for the benefit of cancer patients.”

T3 Pharma’s engineered bacteria stimulate the immune system by delivering selected human proteins directly into cells of the tumor microenvironment. Preclinical studies in a number of tumor models demonstrated a strong impact on tumor progression as well as a durable immune-mediated memory to fight recurring tumors. The clinical development for the lead candidate has been initiated in order to assess the immunotherapy in men with a first clinical trail anticipated for the first half of 2020.

About T3 Pharma
T3 Pharmaceuticals was founded in May 2015 as a spin-off of the University of Basel, Switzerland. The company is focusing on bacteria-based therapies for the treatment of solid tumors.

Previous Post

Polyganics Initiates First-in-Human Trial of LIQOSEAL®, its Innovative Approach for Dural Closure

Next Post

AMAL Therapeutics raises CHF 33.2 Million Series B Round

Related Posts

Emerald Health and Lonza Enter Large-Scale Manufacturing Pact
Drug Development

Emerald Health and Lonza Enter Large-Scale Manufacturing Pact

22nd February 2019
NFC-Label by Schreiner MediPharm for Ypsomed’s SmartPilot Supports Smart Self-Medication
Manufacturing

NFC-Label by Schreiner MediPharm for Ypsomed’s SmartPilot Supports Smart Self-Medication

22nd February 2019
Shimmer Launches Verisense Wearable Sensor Platform for Clinical Trials
Clinical Trials

Shimmer Launches Verisense Wearable Sensor Platform for Clinical Trials

22nd February 2019
Knight Therapeutics invests up to $125m in Latin America-focused Moksha8
Drug Development

Knight Therapeutics invests up to $125m in Latin America-focused Moksha8

21st February 2019
Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials
Clinical Trials

Boehringer Ingelheim and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

13th February 2019
WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership
Manufacturing

WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership

13th February 2019
Next Post

AMAL Therapeutics raises CHF 33.2 Million Series B Round

Latest News

Emerald Health and Lonza Enter Large-Scale Manufacturing Pact
Drug Development

Emerald Health and Lonza Enter Large-Scale Manufacturing Pact

22nd February 2019
NFC-Label by Schreiner MediPharm for Ypsomed’s SmartPilot Supports Smart Self-Medication
Manufacturing

NFC-Label by Schreiner MediPharm for Ypsomed’s SmartPilot Supports Smart Self-Medication

22nd February 2019
Shimmer Launches Verisense Wearable Sensor Platform for Clinical Trials
Clinical Trials

Shimmer Launches Verisense Wearable Sensor Platform for Clinical Trials

22nd February 2019
Knight Therapeutics invests up to $125m in Latin America-focused Moksha8
Drug Development

Knight Therapeutics invests up to $125m in Latin America-focused Moksha8

21st February 2019
Medicine’s just the beginning: eyeforpharma Barcelona 2019 is at record attendance this is going to be the greatest one yet
Manufacturing

Medicine’s just the beginning: eyeforpharma Barcelona 2019 is at record attendance this is going to be the greatest one yet

20th February 2019
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Market Moves OLD
  • Manufacturing
  • News
  • Events & Conferences

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Download Media Pack

Close

x
No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In